Status and phase
Conditions
Treatments
About
The primary purpose of this study is to assess the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib), in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 (camonsertib) in combination with niraparib or olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.
Full description
This is a first-in-human Phase 1b/2, multi-center, open-label, dose-escalation and expansion study to:
After the RP2D and schedule is determined, expansion cohort(s) for RP-3500 (camonsertib) in combination with niraparib or olaparib will be enrolled to study the anti-tumor effect, and further examine the safety, PK, and pharmacodynamic (PD).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
196 participants in 2 patient groups
Loading...
Central trial contact
Gabriela Gomez, MD, MBA; Paul Basciano, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal